Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMG 176 |
Synonyms | |
Therapy Description |
Tapotoclax (AMG 176) selectively inhibits MCL1, potentially resulting in increased tumor cell apoptosis (PMID: 31937611) and reduced tumor growth (PMID: 30254093). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 176 | Tapotoclax|AMG-176|AMG176 | MCL1 Inhibitor 18 | Tapotoclax (AMG 176) selectively inhibits MCL1, potentially resulting in increased tumor cell apoptosis (PMID: 31937611) and reduced tumor growth (PMID: 30254093). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02675452 | Phase I | AMG 176 | AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | DEU | CAN | AUS | 1 |
NCT05209152 | Phase I | AMG 176 + Azacitidine AMG 176 | AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia | Completed | USA | 0 |